Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of imidafenacin tablets for overactive bladder
CTR20251138Phase 3Active
- Sponsor
- Jiangsu Lianhuan Pharmaceutical Co., Ltd.
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of imidafenacin in overactive bladder (OAB), sponsored by Jiangsu Lianhuan Pharmaceutical Co., Ltd.. Started Mar 2025; status: active.
02
Drugs
imidafenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on CTR20251138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251138.